PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26298772-2 2015 We developed a new CAR directed against the disialoganglioside GD2, a surface molecule expressed in neuroblastoma and in other neuroectoderm-derived neoplasms. sialogangliosides 44-62 nuclear receptor subfamily 1 group I member 3 Homo sapiens 19-22 34382720-1 2021 Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. sialogangliosides 0-18 nuclear receptor subfamily 1 group I member 3 Homo sapiens 34-59 34382720-1 2021 Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. sialogangliosides 0-18 nuclear receptor subfamily 1 group I member 3 Homo sapiens 61-64 34382720-1 2021 Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. sialogangliosides 0-18 nuclear receptor subfamily 1 group I member 3 Homo sapiens 79-82 35130560-2 2022 We previously discovered that the disialoganglioside GD2 is highly expressed on H3K27M-mutant glioma cells and demonstrated promising preclinical efficacy of GD2-directed chimeric antigen receptor (CAR) T cells2, providing the rationale for a first-in-human Phase 1 clinical trial (NCT04196413). sialogangliosides 34-52 nuclear receptor subfamily 1 group I member 3 Homo sapiens 198-201